Baxter Recalls Two Lots of IntraVia
Two lots of empty intravenous fluid bags were voluntarily recalled because of the presence of particulates.
Baxter announced on Oct. 22, 2014 that it was voluntarily recalling two lots of IntraVia containers in the US and Canada because of complaints received of particulate matter found inside the fluid path.
IntraVia containers have PVC ports and a sterile fluid path through which intravenous solution travels. Any particulate matter flowing through these containers could cause serious health consequences, Baxter said in a press release.
Affected lots were distributed to customers between Apr. 26, 2013 and June 20, 2013; and between Nov. 27, 2013 and Mar. 10, 2014. Recalled product can be returned for credit to Baxter, and the company encourages patients and healthcare providers to report any adverse events related to the recall.
Source:
FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
